Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 May;81(10):3200–3203. doi: 10.1073/pnas.81.10.3200

Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

S Cabral, S Leis, L Bover, M Nembrot, J Mordoh
PMCID: PMC345249  PMID: 6587345

Abstract

The combined effect of methotrexate (MTX) with dipyridamole, an inhibitor of nucleoside transport, was studied in ascitic Sarcoma 180 cells. It was determined that 10 microM MTX inhibits by greater than 90% deoxy[3H]uridine incorporation into DNA and that this MTX concentration inhibits DNA synthesis as revealed by deoxy[3H]cytidine but not [3H]thymidine incorporation into DNA. Exogenous thymidine (greater than or equal to 1 microM) in the cell culture medium enhances DNA synthesis in nontreated cells and fully restores it in MTX-treated cells, whereas hypoxanthine has no appreciable effect on DNA synthesis. Dipyridamole inhibits deoxy[3H]cytidine and [3H]thymidine uptake by these cells (IC50 = 0.2 and 3 microM, respectively) and blocks the increase in TTP pool produced by 1 microM thymidine in MTX-treated cells (23.1 +/- 4.7 pmol per 1 X 10(6) cells vs. 80.4 +/- 18.9 pmol per 1 X 10(6) cells). Dipyridamole at 10 microM enhances [3H]MTX accumulation by Sarcoma 180 cells and diminishes the efflux of the drug in previously loaded cells. It is suggested that the combination of inhibitors of the de novo pathway for pyrimidine biosynthesis, such as MTX, with inhibitors of the salvage pathway, such as dipyridamole, may increase the cytotoxic activity of MTX alone.

Full text

PDF
3200

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertino J. R. Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1979 Feb;39(2 Pt 1):293–304. [PubMed] [Google Scholar]
  2. Calvert A. H., Bondy P. K., Harrap K. R. Some observations on the human pharmacology of methotrexate. Cancer Treat Rep. 1977 Dec;61(9):1647–1656. [PubMed] [Google Scholar]
  3. Galivan J. Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res. 1979 Mar;39(3):735–743. [PubMed] [Google Scholar]
  4. Henderson E. S., Adamson R. H., Oliverio V. T. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965 Aug;25(7):1018–1024. [PubMed] [Google Scholar]
  5. Howell S. B., Herbst K., Boss G. R., Frei E., 3rd Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res. 1980 Jun;40(6):1824–1829. [PubMed] [Google Scholar]
  6. Howell S. B., Mansfield S. J., Taetle R. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res. 1981 Mar;41(3):945–950. [PubMed] [Google Scholar]
  7. Hryniuk W. M., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969 Nov;48(11):2140–2155. doi: 10.1172/JCI106181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hryniuk W. M. The mechanism of action of methotrexate in cultured L5178Y leukemia cells. Cancer Res. 1975 Apr;35(4):1085–1092. [PubMed] [Google Scholar]
  9. Kessel D., Hall T. C. Effects of persantin on deoxycytidine transport by murine leukemia cells. Biochim Biophys Acta. 1970 Jul 7;211(1):88–94. doi: 10.1016/0005-2736(70)90126-4. [DOI] [PubMed] [Google Scholar]
  10. Kimelberg H. K., Biddlecome S. M., Bourke R. S. Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates. Cancer Res. 1977 Jan;37(1):157–165. [PubMed] [Google Scholar]
  11. Kinahan J. J., Otten M., Grindey G. B. Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine. Cancer Res. 1979 Sep;39(9):3531–3539. [PubMed] [Google Scholar]
  12. Medrano E., Iujvidin S., Mordoh J. Synthesis of phosphatidyl-dCMP in human lymphocytes and its enhancement by chlorpromazine. Eur J Biochem. 1981 May 15;116(2):249–253. doi: 10.1111/j.1432-1033.1981.tb05326.x. [DOI] [PubMed] [Google Scholar]
  13. Mordoh J., Chacón R. D., Filmus J. Isolation of tumor cells from patients with osteosarcoma and analysis of their sensitivity to methotrexate. Cancer Res. 1981 Sep;41(9 Pt 1):3621–3628. [PubMed] [Google Scholar]
  14. Niethammer D., Jackson R. C. Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer. 1975 Dec;11(12):845–854. doi: 10.1016/0014-2964(75)90083-3. [DOI] [PubMed] [Google Scholar]
  15. Pinedo H. M., Zaharko D. S., Bull J. M., Chabner B. A. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976 Dec;36(12):4418–4424. [PubMed] [Google Scholar]
  16. Roberts D., Peck C. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells. Cancer Res. 1981 Feb;41(2):505–510. [PubMed] [Google Scholar]
  17. Scholtissek C. Studies on the uptake of nucleic acid precursors into cells in tissue culture. Biochim Biophys Acta. 1968 Jun 24;158(3):435–447. doi: 10.1016/0304-4165(68)90297-3. [DOI] [PubMed] [Google Scholar]
  18. Schrecker A. W., Mead J. A., Greenberg N. H., Goldin A. Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance. Biochem Pharmacol. 1971 Mar;20(3):716–718. doi: 10.1016/0006-2952(71)90159-6. [DOI] [PubMed] [Google Scholar]
  19. Sirotnak F. M., Donsback R. C. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res. 1975 Jul;35(7):1737–1744. [PubMed] [Google Scholar]
  20. Tattersall M. H., Brown B., Frei E., 3rd The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects. Nature. 1975 Jan 17;253(5488):198–200. doi: 10.1038/253198a0. [DOI] [PubMed] [Google Scholar]
  21. Tattersall M. H., Harrap K. R. Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil. Cancer Res. 1973 Dec;33(12):3086–3090. [PubMed] [Google Scholar]
  22. Zhen Y. S., Lui M. S., Weber G. Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res. 1983 Apr;43(4):1616–1619. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES